Bernardino Mosquera - Catalyst Pharmaceuticals Vice President - Clinical Operations
| CPRX Stock | USD 14.89 0.21 1.43% |
President
Dr. Bernardino Mosquera, M.D. was appointed as Vice President Clinical Operations of Catalyst Pharmaceutical Partners, Inc. effective March 5, 2013. For the last three years, Dr. Mosquera managed his own clinical research consulting company. As an independent consultant, Dr. Mosquera was involved in trials for Alzheimers, Parkinsons, and stroke medications for a multinational pharmaceutical company and several biotech companies. Prior to his time as an independent consultant, for approximately five years Dr. Mosquera worked first with Amgen and later as a dedicated contractor for Amgen on a number of Phase 3 trials in the oncology area. Prior to his time with Amgen, Dr. Mosquera worked with Kos Pharmaceuticals where he was involved in all aspects of clinical trial management for two Phase 3 trials, where he was responsible for CRO selection, site selection, vendor management, creation of study documents, IRB submissions, trial management, and CRA management since 2013.
| Age | 46 |
| Tenure | 11 years |
| Address | 355 Alhambra Circle, Coral Gables, FL, United States, 33134 |
| Phone | 305 420 3200 |
| Web | https://www.catalystpharma.com |
Catalyst Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.1283 % which means that it generated a profit of $0.1283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2075 %, meaning that it created $0.2075 on every $100 dollars invested by stockholders. Catalyst Pharmaceuticals' management efficiency ratios could be used to measure how well Catalyst Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.27 in 2024. Return On Capital Employed is likely to rise to 0.23 in 2024. At this time, Catalyst Pharmaceuticals' Asset Turnover is fairly stable compared to the past year.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Michael Yang | ACADIA Pharmaceuticals | 55 | |
| Chids Mahadevan | BioXcel Therapeutics | 45 | |
| Joan Wood | Sarepta Therapeutics | N/A | |
| Jayant Aphale | Sarepta Therapeutics | 54 | |
| Austin Kim | ACADIA Pharmaceuticals | 60 | |
| Amy Broidrick | Viking Therapeutics | N/A | |
| Srdjan Stankovic | ACADIA Pharmaceuticals | 61 | |
| Maria Pasquale | Incyte | 52 | |
| Dashyant Dhanak | Incyte | 63 | |
| Patrick Haley | Exelixis | 42 | |
| Catherine StehmanBreen | Sarepta Therapeutics | 53 | |
| Luca Rastelli | BioXcel Therapeutics | 49 | |
| Wendy Rieder | Madrigal Pharmaceuticals | 46 | |
| Wenqing Yao | Incyte | 55 | |
| Guriqbal Basi | Sarepta Therapeutics | 60 | |
| Christopher Senner | Exelixis | 56 | |
| Richard Levy | Incyte | 57 | |
| Susan Hubbard | Exelixis | N/A | |
| Elena Ridloff | ACADIA Pharmaceuticals | 38 | |
| Cedric OGorman | Axsome Therapeutics | 42 | |
| Gregory Zante | Viking Therapeutics | 53 | |
Management Performance
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.13 |
Catalyst Pharmaceuticals Leadership Team
Elected by the shareholders, the Catalyst Pharmaceuticals' board of directors comprises two types of representatives: Catalyst Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catalyst. The board's role is to monitor Catalyst Pharmaceuticals' management team and ensure that shareholders' interests are well served. Catalyst Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catalyst Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pete Sr, Vice Sales | ||
| Mary Coleman, VP Relations | ||
| Donald Denkhaus, Director | ||
| Gary MD, Chief Officer | ||
| Jeffrey Carmen, Executive Officer | ||
| Charles OKeeffe, Lead Independent Director | ||
| Bernardino Mosquera, Vice President - Clinical Operations | ||
| Alicia Grande, CFO, Vice President Treasurer | ||
| David Tierney, Independent Director | ||
| Preethi Sundaram, Chief Officer | ||
| Daniel Brennan, Chief Commercial Officer | ||
| Philip Coelho, Independent Director | ||
| Richard Daly, Interim Chief Commercial Officer, Director and Member of Nominating and Corporate Governance Committee | ||
| Philip Schwartz, Co Sec | ||
| CMA CPA, VP, Officer | ||
| Richard MBA, CEO President | ||
| Stanley MD, Senior Discovery | ||
| Michael CPA, Executive CFO | ||
| Gary Ingenito, Chief Medical Officer | ||
| David Connolly, IR Contact Officer | ||
| Douglas Winship, Vice President - Regulatory Operations | ||
| Patrick McEnany, Co-Founder, Chairman, CEO and Pres | ||
| Steven Miller, COO and Chief Scientific Officer | ||
| Brian Elsbernd, Chief Compliance Officer, Chief Legal Officer | ||
| David Caponera, Vice President - Patient Advocacy & Reimbursement | ||
| David Muth, Chief Commercial Officer and Executive VP | ||
| Brian JD, Chief Officer |
Catalyst Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catalyst Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.38 % | ||||
| Current Valuation | 1.62 B | ||||
| Shares Outstanding | 118.01 M | ||||
| Shares Owned By Insiders | 6.21 % | ||||
| Shares Owned By Institutions | 73.40 % | ||||
| Number Of Shares Shorted | 6.27 M | ||||
| Price To Earning | 23.62 X |
Pair Trading with Catalyst Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Catalyst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Catalyst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Catalyst Stock
| 0.66 | SBFMW | Sunshine Biopharma | PairCorr |
The ability to find closely correlated positions to Catalyst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Catalyst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Catalyst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Catalyst Pharmaceuticals to buy it.
The correlation of Catalyst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Catalyst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Catalyst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Catalyst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Complementary Tools for Catalyst Stock analysis
When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is Catalyst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Catalyst Pharmaceuticals. If investors know Catalyst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Catalyst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.346 | Earnings Share 0.63 | Revenue Per Share 3.747 | Quarterly Revenue Growth 0.82 | Return On Assets 0.1283 |
The market value of Catalyst Pharmaceuticals is measured differently than its book value, which is the value of Catalyst that is recorded on the company's balance sheet. Investors also form their own opinion of Catalyst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Catalyst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Catalyst Pharmaceuticals' market value can be influenced by many factors that don't directly affect Catalyst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Catalyst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Catalyst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Catalyst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.